Iamin-IB: Began Phase I/II trial dose-ranging trial of safety and efficacy in 50 patients with mild or moderate disease

ProCyte Corp. (PRCY), Kirkland, Wash. Product: Iamin-IB, retention enema form of the anti-inflammatory copper-peptide agent, which activates tissue repair enzymes Indication: Inflammatory bowel diseas...